Alterity Therapeutics to Present New Data on ATH434 at the W

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...

Related Keywords

Colorado , United States , California , Denver , Australia , San Francisco , Melbourne , Victoria , Boston , Massachusetts , American , Americans , Hannah Howlett , Remy Bernarda , Margaret Bradbury , Danielo Claassen , David Stamler , Daniel Claassen , Vanderbilt University Medical Center , Securities Exchange , Parkinson Foundation , European Commission , System Atrophy National Institute Of Neurological Disorders , Nonclinical Development , Department Of Pharmaceutical Sciences , Nasdaq , World Orphan Drug Congress United States , American Academy Of Neurology , Alterity Therapeutics , National Institute Of Health , Wayne State University , Unique Iron Targeting Drug , Treating Friedreich , Pharmaceutical Sciences , Wayne State , American Academy , Novel Inhibitor , Synuclein Aggregation , Multiple System Atrophy , Chief Executive Officer , Plight Chain , Clinical Progression , Early Multiple System , Vanderbilt University Medical , Clinical Phase Small Molecule , Moderate Affinity , Disease Model , Vice President , System Atrophy , National Institute , Neurological Disorders , Mouse Model , Disease Information Page , Multiple System , Media Contacts , Securities Act , Securities Exchange Act , Annual Report , Markets ,